Discussion About Bufei Huoxue Decoction Combined Salmeterol Fluticasone Treatment on Chronic Obstructive Pulmonary Disease in o Curative Effect and Action Mechanism

CHEN Xiang-zhong; KE Jia; LIU Quan; SHENG Lei

doi:10.13422/j.cnki.syfix.2014090220

您当前的位置：

首页 >

文章列表页 >

Discussion About Bufei Huoxue Decoction Combined Salmeterol Fluticasone Treatment on Chronic Obstructive Pulmonary Disease in o Curative Effect and Action Mechanism

更新时间：2024-01-04

- Discussion About Bufei Huoxue Decoction Combined Salmeterol Fluticasone Treatment on Chronic Obstructive Pulmonary Disease in o Curative Effect and Action Mechanism
- Chinese Journal of Experimental Traditional Medical Formulae Vol. 20, Issue 9, Pages: 220-223(2014)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：10.13422/j.cnki.syfix.2014090220
  CLC：
- Published：2014
- 稿件说明：
移动端阅览
CHEN Xiang-zhong, KE Jia, LIU Quan, et al. Discussion About Bufei Huoxue Decoction Combined Salmeterol Fluticasone Treatment on Chronic Obstructive Pulmonary Disease in o Curative Effect and Action Mechanism[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(9): 220-223.
DOI：

CHEN Xiang-zhong, KE Jia, LIU Quan, et al. Discussion About Bufei Huoxue Decoction Combined Salmeterol Fluticasone Treatment on Chronic Obstructive Pulmonary Disease in o Curative Effect and Action Mechanism[J]. Chinese journal of experimental traditional medical formulae, 2014, 20(9): 220-223. DOI： 10.13422/j.cnki.syfix.2014090220.

摘要

目的：探讨补肺活血汤联合沙美特罗替卡松治疗慢性阻塞性肺疾病（COPD）稳定期的疗效及对α1-抗胰蛋白酶（α1-AT）和白细胞介素-8（IL-8）的影响。方法：将诊断明确的COPD患者72例随机按接诊顺序分为观察组与对照组各36例。两组均给予西医常规吸氧、祛痰等治疗。对照组采用沙美特罗替卡松，1吸/次，2次/d。观察组在对照组治疗的基础上加用补肺活血汤，1剂/d。两组疗程均为12周。进行治疗前后肺功能检测，采用6 min步行距离（6 MWD）评定运动能力，采用COPD生存质量评分表（CAT问卷）评定生活质量，检测治疗前后α1-抗胰蛋白酶（α1-AT）和白细胞介素-8（IL-8）水平。结果：经参照单位（Ridit）分析观察组总体疗效优于对照组（P<0.05）；治疗后观察组用力肺活量（FVC）、1 s用力呼气容积（FEV1）和FEV1/FVC均高于对照组（P<0.01）；治疗后观察组6 MWD优于对照组（P<0.01）；治疗后观察组CAT评分低于对照组（P<0.01）；观察组α1-AT较治疗前升高（P<0.01），并高于治疗后对照组（P<0.01）；治疗后两组血清IL-8水平均较治疗前下降（P<0.01），治疗后观察组IL-8水平低于对照组（P<0.01）。结论：补肺活血汤联合沙美特罗替卡松能改善COPD稳定期患者肺功能，提高患者运动能力和生活质量，临床疗效显著，其作用机制可能与抑制炎性反应有关。

Abstract

Objective: The purpose is to discuss the efficacy of Bufei Huoxue decoction combined Salmeterol Fluticasone on cure of chronic obstructive pulmonary (COPD) curative effect and the influence of α1-antitrypsin (α1-AT) and interleukin-8 (IL-8). Method: The 72 patients diagnose clearly with COPD were randomly divided into control group and observation group. Each group were (36 cases). Both groups were given western medicine treatment as routine oxygen

eliminating phlegm et.Patients in control group took Salmeterol Fluticasone

1 inhalation/time

2 does/day.on the basis of the control treatment

patients in observation group plus therapy of Bufei Huoxue decoction

1 does/day.Treatment courses for the two groups continued 12 weeks.Detect lung function

evaluate athletic ability by 6 min walking distance (6 MWD) and adopt COPD life quality scale (CAT questionnaire) to evaluate life quality before and after treatment.Besides test the level of α1-AT and IL-8 around treatment. Result: Analyzing by Ridit

the total curative effect of the observation group was superior to the control group (P<0.05)

after treatment

forced vital capacity (FVC) of the observation group

the FEV1 volume of the observation group and FEV1/FVC were all higher than that of the control group (P<0.01)

after treatment 6 MWD of the observation group was superior to the control group (P<0.01)

and the grade of CAT of the observation group was lower than that of the control group (P<0.01)

and alpha 1-antitrypsin of the observation group was higher than that before therapy (P<0.01)

which higher than that of the control group (P<0.01)

Besides

the level of Serum IL-8 of the two groups were lower than that before therapy (P<0.01)

and level of Serum IL-8 of the observation group was lower than that of control group (P<0.01). Conclusion: At the COPD stable phase

it can improve patients' lung function when Bufei Huoxue decoction combined with Salmeterol Fluticasone

and improve the exercise capacity and quality of life of patients

there was a significant curative effect

and the mechanism of action may be related to inhibiting inflammatory response.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Improvement of Lung Function in Rats with Idiopathic Pulmonary Fibrosis by Shengxiantang via Regulating Cell Senescence Mediated by Wnt3a/β-catenin Signaling Pathway

Clinical Efficacy Evaluation of Tanreqing Injection Combined with Ceftazidime in Treatment of Phlegm Heat Obstructing Lung Syndrome in Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Network Meta-analysis of Efficacy of Five Classical Prescriptions for Acute Attack of Asthma in Children

Clinical Effect of Modified Ditantang Combined with Acupuncture on Syndrome of Phlegm and Blood Stasis Blocking Collaterals of Dysphagia After Apoplexy

Effect and Safety of Modified Buzhong Yiqitang on VEGF， IGF-1， TGF-β₁， and Immune Function in Postoperative Patients with Non-small Cell Lung Cancer After Chemotherapy

Related Author

YAN Yanan

LIANG Yulei

WANG Jiepeng

FANG Chaoyi

ZHANG Mengmeng

LI Qiao

XIONG Qingyong

LI Jiayao

Related Institution

Hebei Key Laboratory of Integrated Traditional Chinese and Western Medicine for Lung Disease Research

Hebei University of Chinese Medicine

Anhui College of TCM Respiratory Disease Prevention and Treatment Research Institute

Key Laboratory of TCM for the Prevention and Treatment of Major Pulmonary Diseases， Anhui Provincial Department of Education Key Laboratory

The First Affiliated Hospital of Anhui University of Chinese Medicine

AI问答

Postal code：100700
Tel：010-84076882 Email：syfjx_2010@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备11006657号-10 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰